SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Melanoma: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Melanoma.

Related Posts

Regeneron and Sanofi’s Dupixent bags fifth drug label i...

Feb 16, 2024

Korro Bio enters merger deal with Frequency Therapeutics

Jul 17, 2023

To prevent preeclampsia, experts push for broader blood...

Apr 29, 2023